Product Name: Isavuconazonium sulfate CAS NO: 946075-13-4
Glycine,N-methyl-,[2-[[[1-[1-[(2R,3R)-3-[4-(4-cyanophenyl)-2-thiazolyl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-4H-1,2,4-triazolium-4-yl]ethoxy]carbonyl]methylamino]-3-pyridinyl]methyl ester, sulfate (1:1);
Chemical & Physical Properties:
Appearance : White to off-white powder
On March 6, 2015, the U.S. FDA gave priority to Japan Astellas’ new antifungal drug Isavuconazoniumsulfate, which was marketed under the trade name Cresemba. It is used to treat invasive aspergillosis and mucormycosis. These two fungal infections mostly occur in patients with blood cancer. Isaconazole sulfate is the prerequisite drug of isaconazole. After entering the body, it is metabolized into isaconazole and exerts an antifungal mechanism. Isaconazole sulfate is available in oral and injection form. Isaconazole is safer and more effective than Pfizer's voriconazole (Vfend), and has lower patient mortality.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.